Eisai And Merck Announce FDA Approval Of Lenvima Capsules - Quick Facts

Eisai Inc. (ESALY.PK) and Merck & Co. Inc. (MRK) said that the U.S. Food and Drug Administration approved the kinase inhibitor Lenvima, or lenvatinib, for the first-line treatment of patients with unresectable hepatocellular carcinoma or HCC.

from RTT - Biotech https://ift.tt/2BibGKl
via IFTTT